Overcoming Treatment Challenges in Advanced Breast Cancer

Seminars in Oncology Nursing

Volumn 23, Issue SUPPL. 2, 2007, Pages

  Harkins, Barbara ^a   Geyer Jr , Charles E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 36549018079     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.10.003     Document Type: Article

References (14)

1. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319 (2004) 1-11
2. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 suppl 2 (2004) 21-26
3. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
4. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
5. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
6. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
7. Fountzilas G., Razis E., Tsavdaridis D., et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 4 (2003) 120-125
8. Gelmon K.A., Mackey J., Verma S., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5 (2004) 52-62
9. Garcia-Saenz J.A., Martin M., Puente J., et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 6 (2005) 325-329
10. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 (2006) 1630-1639
11. Blackwell K.L., Burstein H., Pegram M., et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. [abstract]. J Clin Oncol 23 suppl 16 (2005) 3004
12. Schwartz G., Chu Q.S.C., Hammond L.A., et al. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol 23 (2004) 3070
13. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
14. Geyer C.E., Martin A., Newstat M., et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol 25 suppl 18 (2007) 1035